LL-37 (Cathelicidin) — Dosing, Cycles, Half-Life & Side Effects
LL-37 (Cathelicidin) is an antimicrobial peptide with a half-life of 4-6 hours. Human cathelicidin antimicrobial peptide with broad-spectrum activity against bacteria, viruses, and fungi. Also exhibits immunomodulatory, wound healing, and anti-biofilm properties. This page is educational harm-reduction reference compiled from peer-reviewed literature — not medical advice, not an endorsement, not a recommendation to use. Consult a licensed clinician before any decision.
Quick Facts
| Class | Antimicrobial Peptides |
|---|---|
| Half-life | 4-6 hours |
| Hepatotoxicity | None |
| Suppression | 0/10 |
Typical Dosing Ranges
Common dose range: 50-100mcg/day subcutaneous
Cycle length: 2-4 weeks
Dose ranges are compiled from published pharmacokinetic studies and community-reported usage. Where a value is community-reported rather than clinically studied, this page and its structured data flag it. Lower end of any range is always the safer starting point.
Stacking Considerations
- No structural stacking blockers. Standard harm-reduction rules apply: minimize total androgen load, minimize oral exposure, and monitor bloodwork.
PCT Requirements
- Never stack two SERMs. Extend a single SERM (tamoxifen OR enclomiphene/clomiphene) rather than combining.
- Use the cycle planner to generate a full protocol based on your complete stack, not this compound alone.
Side Effect Profile
- Limited clinical trial data for therapeutic use
- Can be pro-inflammatory at high doses
- Expensive
- Requires injection
- Potential for autoimmune activation
Known Interactions
No compound-specific interactions are catalogued in the current matrix. This does not mean no risk exists — it means there is no curated pairwise entry. Browse the full interaction matrix to cross-reference manually.
Related compounds
Monitoring (Bloodwork & Vitals)
- Comprehensive metabolic panel (baseline, mid-cycle, post-cycle)
- Lipid panel (total cholesterol, HDL, LDL, triglycerides)
- CBC (hemoglobin, hematocrit — watch for erythrocytosis)
- Sex-hormone panel (Total T, Free T, Estradiol sensitive, SHBG, LH, FSH)
- Blood pressure (weekly self-check; flag systolic >140 or diastolic >90)
Baseline bloodwork is recommended before any cycle. Discontinue if liver enzymes exceed 3× upper limit of normal or if hematocrit exceeds 54%.
Frequently Asked Questions
What is the half-life of LL-37 (Cathelicidin)?
LL-37 (Cathelicidin) has a half-life of approximately 4-6 hours. This figure is used to determine injection frequency (for esters) and post-cycle clearance timing.
What is the typical dose range for LL-37 (Cathelicidin)?
Commonly reported ranges for LL-37 (Cathelicidin): 50-100mcg/day subcutaneous. Cycle length: 2-4 weeks. These are compiled from published studies and community-reported usage — individual response varies and lower end is always preferred.
Does LL-37 (Cathelicidin) suppress natural testosterone?
LL-37 (Cathelicidin) causes minimal suppression of the HPTA axis (score 0/10). PCT may still be advisable depending on stack and duration.
What is LL-37 (Cathelicidin) typically used for?
LL-37 (Cathelicidin) is commonly used for: Immune support (experimental), Infection management (research), Wound healing. Intended-use context does not imply safety — every use case carries the same underlying pharmacological risks.
Is LL-37 (Cathelicidin) legal?
LL-37 (Cathelicidin) is a controlled substance in many jurisdictions (typically Schedule III in the US when it is an anabolic androgenic steroid). StackItSmart does not provide sourcing information. Possession, import, and use without a prescription carry legal consequences that vary by country and state.
Citations
- Vandamme D et al.. 2012. Cell Immunol — Human cathelicidin antimicrobial peptide LL-37 review; limited clinical application data
- Vandamme D, et al. A comprehensive summary of LL-37, the factotum human cathelicidin peptide. Cell Immunol. 2012;280(1):22-35. PMID: 23246832
- Fabisiak A, Murawska N, et al. LL-37: Cathelicidin-related antimicrobial peptide with pleiotropic activity. Pharmacol Rep. 2016. PMID: 27117377
Disclaimer
StackItSmart is an independent harm-reduction reference. The content above is compiled from peer-reviewed literature and is not medical advice, not an endorsement, and not a recommendation to use LL-37 (Cathelicidin). Performance-enhancing compounds carry legal, endocrine, cardiovascular, and hepatic risks. Consult a licensed clinician before any decision. StackItSmart does not provide sourcing, procurement, or dosing prescriptions.